These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27609087)

  • 1. Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation.
    Buetow L; Tria G; Ahmed SF; Hock A; Dou H; Sibbet GJ; Svergun DI; Huang DT
    BMC Biol; 2016 Sep; 14(1):76. PubMed ID: 27609087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl.
    Dou H; Buetow L; Hock A; Sibbet GJ; Vousden KH; Huang DT
    Nat Struct Mol Biol; 2012 Jan; 19(2):184-92. PubMed ID: 22266821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.
    Bonita DP; Miyake S; Lupher ML; Langdon WY; Band H
    Mol Cell Biol; 1997 Aug; 17(8):4597-610. PubMed ID: 9234717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
    Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
    Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
    Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl. A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor.
    Bartkiewicz M; Houghton A; Baron R
    J Biol Chem; 1999 Oct; 274(43):30887-95. PubMed ID: 10521482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene.
    Thien CB; Langdon WY
    Oncogene; 1997 May; 14(18):2239-49. PubMed ID: 9174060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination.
    Visser GD; Lill NL
    Exp Cell Res; 2005 Dec; 311(2):281-93. PubMed ID: 16246327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations.
    Kassenbrock CK; Anderson SM
    J Biol Chem; 2004 Jul; 279(27):28017-27. PubMed ID: 15117950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
    Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
    Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/β-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.
    Kumaradevan S; Lee SY; Richards S; Lyle C; Zhao Q; Tapan U; Jiangliu Y; Ghumman S; Walker J; Belghasem M; Arinze N; Kuhnen A; Weinberg J; Francis J; Hartshorn K; Kolachalama VB; Cifuentes D; Rahimi N; Chitalia VC
    Am J Pathol; 2018 Aug; 188(8):1921-1933. PubMed ID: 30029779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
    Andoniou CE; Thien CB; Langdon WY
    EMBO J; 1994 Oct; 13(19):4515-23. PubMed ID: 7925293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins.
    Yokouchi M; Kondo T; Sanjay A; Houghton A; Yoshimura A; Komiya S; Zhang H; Baron R
    J Biol Chem; 2001 Sep; 276(37):35185-93. PubMed ID: 11448952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
    Miyake S; Lupher ML; Andoniou CE; Lill NL; Ota S; Douillard P; Rao N; Band H
    Crit Rev Oncog; 1997; 8(2-3):189-218. PubMed ID: 9570294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
    Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
    PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b.
    Kobashigawa Y; Tomitaka A; Kumeta H; Noda NN; Yamaguchi M; Inagaki F
    Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20579-84. PubMed ID: 22158902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential ubiquitin binding of the UBA domains from human c-Cbl and Cbl-b: NMR structural and biochemical insights.
    Zhou ZR; Gao HC; Zhou CJ; Chang YG; Hong J; Song AX; Lin DH; Hu HY
    Protein Sci; 2008 Oct; 17(10):1805-14. PubMed ID: 18596201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.
    Aranaz P; Hurtado C; Erquiaga I; Miguéliz I; Ormazábal C; Cristobal I; García-Delgado M; Novo FJ; Vizmanos JL
    Haematologica; 2012 Aug; 97(8):1234-41. PubMed ID: 22315494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
    Andoniou CE; Thien CB; Langdon WY
    Oncogene; 1996 May; 12(9):1981-9. PubMed ID: 8649859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
    Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
    Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.